BENIGN AND MALIGNANT MESENCHYMAL TUMORS: MUSCLE AND OTHER CELL LINE ORIGINS
KEY POINTS
- Benign and malignant tumors of muscle and other mesenchymal origin usually do not distinguish themselves from other malignancies based on appearance alone.
- Sarcomas may have an indolent looking margin especially on MRI that belies their true nature.
- Synovial cell sarcomas do not arise in joints.
RHABDOMYOSARCOMA
Clinical Perspective and Pathology
Rhabdomyosarcoma is the most common lesion of striated muscle cell origin arising in the head and neck region.1 The head and neck, in general, is the most common site of origin of these tumors. In children, it is the most common soft tissue malignancy of the head and neck occurring predominantly in patients between 2 and 12 years of age.2,3 It is unusual to see a rhabdomyosarcoma in those <1 year of age; thus, it becomes extremely important not to mistake infantile torticollis or fibromatosis colli (Chapter 37) for rhabdomyosarcoma.
Rhabdomyosarcoma variants recapitulate the embryogenesis of skeletal muscle that progresses through small round cell and spindle cell phases to become a mature, multinucleated muscle fiber. The least differentiated of these tumors, embryonal rhabdomyosarcoma, is composed of small, round cells and in the past may be mistaken histopathologically for lymphoma, melanoma, and fibrosarcoma, among others.1–4 Immunohistochemical studies have, however, eliminated most of the ambiguity in the diagnosis of “small round cell” and “spindle cell” lesions.
About one third of rhabdomyosarcomas arise in the orbit and periorbital soft tissues (Fig. 35.1). The neck and deep facial structures (Figs. 35.2–35.6), nasopharynx, tongue and soft palate, middle ear, and mastoid region (Fig. 35.7) each account for roughly 10% to 12% of the remainder. The remaining one third are scattered among the sinuses, nasal cavity, mandible, oral cavity (Fig. 35.2), floor of the mouth (Fig. 35.3), salivary glands, larynx, and hypopharynx.
Rhabdomyosarcomas are generally mildly vascular well-circumscribed lesions with multilobular margins as seen on computed tomography (CT) and magnetic resonance imaging (MRI).4,5 The well-circumscribed margins as typically represented on MRI are deceptive in these malignancies.
Rhabdomyosarcomas are currently treated, with ever-improving success, by a combination of chemotherapy and radiation therapy.1,2 Over the last 10 to 15 years, surgery has been relegated to an adjunctive role in most cases.
Imaging Appearance
These highly cellular lesions appear much brighter than muscle on T2-weighted MRI and may even be hyperintense to fat4,5 (Figs. 35.1 and 35.2). They are about muscle equivalent on T1-weighted images. The tumor cells are frequently accompanied by a loose stroma that may contribute to the tendency for the lesions to be bright on T2-weighted images. Even though these tumors are brighter than muscle on T2-weighted images, they will not, as a rule, approach the signal intensity seen in typical inflammatory polyps. Rhabdomyosarcomas arising on mucosal surfaces may mimic inflammatory polyps or other polypoid mucosal masses (Fig. 35.8) on physical examination. When this occurs in the nasal cavity and nasopharynx, imaging evidence of deep infiltration suggesting malignancy or an enhancement pattern suggestive of polyps or normal lymphoid tissue suggesting the benign alternative may help in making this differentiation. The latter findings are easier to appreciate on contrast-enhanced magnetic resonance (CEMR) than on contrast-enhanced computed tomography (CECT). Enlarged vessels may be present and lead to the mistaken impression of the lesion being a juvenile angiofibroma or hemangiopericytoma. The aggressive growth pattern into surrounding soft tissues and clinical features should make the differential diagnosis straightforward in almost all cases. On non–contrast-enhanced CT, they are about muscle slightly hypodense to about equivalent to muscle density (Fig. 35.6) and may show mild to marked enhancement (Fig. 35.7). Necrosis is a common regressive change in larger tumors (Figs. 35.3 and 35.7).